Specialising in pharmaceuticals, the site offers a variety of services including mixing and blending, storage, transportation, and quality-assured repackaging of active ingredients.
Almirall S.A. a global biopharmaceutical company dedicated to medical dermatology, has announced that NICE has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.
Within the new group of companies, Konapharma now complements the services of packaging company Allpack and Rhenochem, a family-owned company with decades of extensive experience and expertise in the global pharmaceutical industry.
This GLP-1R / CRE Luciferase Reporter HEK293 cell line has been engineered to monitor activation of GLP-1R in cells by measuring luciferase activity, making it useful for cell-based binding assays and screening for human GLP-1R agonists.
The agreement spans the Republic of South Africa and members of the GCC alliance, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
Johnson & Johnson Innovative Medicine have announced its strengthened commitment in Italy, with a projected investment of 580 million euros over the next five years, of which €125 million will support an increase in production capacity.
Cycle Pharmaceuticals a rapidly growing pharmaceutical company focused on treatments for the underserved rare disease patient community, have confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc.
Ecolab have announced that its Purolite resin business, together with Repligen Corporation has commercially launched Purolite’s DurA Cycle, a protein A chromatography resin for large-scale purification processes.
Almac Group, the global contract pharmaceutical development and manufacturing organisation, has announced its financial results for year ending 30 September 2023.
Eli Lilly and Company have announced that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion.
Johnson & Johnson have announced that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million.
